Disease Treatment in Korea

Q: What side effects are common?

Usually transient: low-grade fever, chills or discomfort at the administration site. Report everything to the team.

Q: Why do prices differ so much?

Differences come from cell dose, number of sessions, testing depth and included services; compare line by line.

Q: Must follow-up happen in Korea?

Most follow-up can be done at home via labs, but agree in advance on sharing results with the Korean team.

Q: What does an unusually low price mean?

It may reflect a low cell count or an unregulated process; ask for written details.

Q: What if I am declined?

Treat it as useful information: refocus on standard care and ask about recruiting trials.

Q: Do donor cells carry infection risk?

Accredited facilities screen donors and test each lot rigorously; ask to see the documentation.

Q: What if the cells fail to reach target?

Recollection or rescheduling may be needed; clarify the cost policy for that before paying.

Q: Can they be combined?

Some providers offer that, but supporting evidence is thin; beware added cost without data.

Korea's world-leading disease treatment innovation — from cancer and cardiac care to neurosurgery and cell therapy.

In this category

Explainers, comparisons and guides for this category — not provider profiles.

Cover: a nurse measuring an older man's blood pressure in a clinic

Hypertensive kidney damage: any regeneration plan starts with blood pressure

Chronic hypertension thickens and narrows renal vessels, reducing perfusion until tissue atrophies and scars. Outcomes improve most when pressure is brought to target alongside sodium restriction and kidney-protective drugs. Stem cell infusion is investigational and must not replace pressure control.

Cover: a dialysis machine and chair in a quiet renal unit

Dialysis patients and stem cells: what to know before believing any advert

Patients on dialysis have lost nearly all kidney function, and no clinical evidence shows stem cell infusion can free them from it. Any guarantee of that should be treated as a red flag. What genuinely helps is dialysis adequacy, nutrition, phosphate control and transplant evaluation.

Cover: an elderly Korean woman walking in a park with family support

Age-related kidney decline: safe and sensible approaches for older adults

Filtration naturally falls roughly 0.5 to 1 unit a year after age 40. Protein leakage or a faster drop signals disease that needs treatment. Older adults considering stem cell infusion for kidney disease need careful assessment of cardiac risk, frailty and drug interactions first.

Cover: a transplant patient reviewing medication with a nurse by a hospital window

After a kidney transplant: cell therapy and the immune risks that need special care

Transplant recipients take lifelong immunosuppression to prevent rejection, which makes any cell therapy unusually complex: it can disturb immune balance and drug levels. Nobody in this group should decide alone — the decision belongs with the transplant team.

Cover: medication blister packs beside an injectable vial on a white table

Stem cells versus standard kidney drugs: evidence, cost and risk compared

Standard drugs such as ACEi/ARB and SGLT2 inhibitors are backed by large randomised trials showing real slowing of kidney decline, while stem cell infusion remains investigational with limited data and much higher cost. The rational path is to maximise standard therapy first, then consider cell therapy only as a supervised adjunct.

Cover: a scientist pipetting a clear solution into lab tubes

Stem cells versus exosomes for the kidney: the difference and the unknowns

Stem cells are living cells that respond to the body's environment; exosomes are nanoscale vesicles released by cells, carrying proteins and RNA but not alive. Both are studied for reducing inflammation and supporting kidney regeneration, yet neither is proven superior in CKD and neither is standard care.

Cover: two cryogenic cell vials side by side on a cold metal surface

Autologous versus allogeneic cells: choosing for kidney disease treatment

Autologous cells minimise immune rejection risk but need weeks of culture and depend on the patient's own cell quality. Allogeneic cells are faster to access with more consistent quality, but raise immune considerations. EHL Bio's KDSTEM is autologous, grown from the patient's own urine-derived cells.

Cover: a Korean physician reviewing a patient assessment checklist

Who is and is not a candidate for stem cell injection in kidney disease

Likely candidates are stable mid-stage CKD patients already on full standard therapy, without active cancer or severe infection, who understand this is investigational. Poor candidates include dialysis patients, those with active malignancy, pregnant women, and anyone expecting a cure.

Cover: a patient writing questions in a notebook during a consultation

12 questions to ask before paying for stem cell kidney treatment

Before agreeing to a stem cell kidney programme, work through twelve questions: legal status of the product, cell source, GMP standards, dose and number of sessions, outcome measures, adverse-event handling, total cost and the follow-up plan after you fly home. Vague answers are reason enough to wait.

Cover: a South Korean government institution building in Seoul

Korean regulation of stem cell treatment for kidney disease: what is and is not allowed

Stem cell injection for kidney disease in South Korea sits under the advanced regenerative medicine framework: cells must be manufactured in a licensed GMP facility, and administration must fall within an approved clinical study or case-by-case review, not a freely advertised commercial service.

Cover: a traveller with luggage and a medical document folder at Incheon airport

Planning a Seoul trip for kidney treatment: schedule, documents and care while you stay

Budget at least five to seven days in Seoul for testing, physician assessment and post-procedure follow-up. Bring historical labs, a medication list, arrange a medical interpreter, and plan for the possibility that the procedure is postponed if kidney values or blood pressure are unsuitable.

Cover: a calculator and an itemised treatment quotation on a desk

Cost of stem cell kidney treatment: how to read a quotation properly

A transparent quotation for stem cell kidney treatment separates at least five parts: assessment, cell collection and preparation, GMP manufacturing, administration and same-day care, and follow-up. A single lump sum with no breakdown should prompt a request for detail before deciding.